Title
Category
Credits
Event date
Cost
- CMHC
- 1.00 ACPE ...See more
$0.00
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis.
- CMHC
- 0.50 ACPE ...See more
$0.00
This clinical brief was developed from a presentation at the 19th CMHC Annual Congress held from October 17-19, 2024 in Boston, MA. The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.
- CMHC
- 0.50 ACPE ...See more
$0.00
This interactive case-based program focuses on managing patients with cardiorenal metabolic comorbidities. Participants will explore evidence-based guidelines, therapeutic strategies, and risk assessment tools to improve cardiovascular and kidney outcomes in patients with CKD, type 2 diabetes, and cardiovascular disease. Engaging decision-making scenarios and expert-led discussions will enhance practical skills and interdisciplinary approaches to optimize patient care.